Earnings per share for the last twelve months: Processa Pharma (PCSA)

Outsourcing development and testing to external contractors creates operational dependency, and the rolling annual earnings per share chart on GURU.Markets is available for analysis, where -5.62 serves as the current metric level. A stable staff of oncologists and the potential of the high-margin PCS platform upon FDA approval allow Processa Pharmaceuticals (PCSA) to effectively scale its business in the breast cancer treatment sector.

PCSA (Processa Pharma) Net earnings per share for the last 12 months history from 07/04/2022 to 11/10/2026

Analytical breakdowns for Processa Pharmaceuticals Inc. (PCSA)

- stock price and consensus target price:

Stock Price Processa Pharma|PCSA - Analyst Consensus Forecast

- company stock exchange capitalization indicators:

Market Value Processa Pharmaceuticals, Inc.|PCSA - Business Value

- shareholders' equity book value data:

Book Value per Share Processa Pharmaceuticals|PCSA - Company Net Assets|Market Capitalization to Book Value Ratio processapharmaceuticals.com|PCSA - Company Assets

- debt burden and liquidity indicators:

Debt to Equity Processa Pharmaceuticals|PCSA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Processa Pharma|PCSA - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Processa Pharmaceuticals, Inc.|PCSA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Processa Pharmaceuticals|Quick Ratio processapharmaceuticals.com

- net income and valuation multiples indicators:

PCSA - Net Income|Projected Future Earnings Processa Pharmaceuticals|PCSA - Market Cap to Earnings|Future Price to Earnings Processa Pharma|PCSA - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Processa Pharmaceuticals, Inc.|PCSA - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Processa Pharmaceuticals|PCSA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months processapharmaceuticals.com|PCSA - Earnings per share increase in current year|Net earnings per share growth forecast for next year Processa Pharmaceuticals

Summary company analysis:PCSA - processapharmaceuticals.com

Mass-produced product of Processa Pharma

Annual net earnings per share measure the actual portion of income attributable to a single security. This indicator separates actual business efficiency from market hype. By analyzing the 12-month EPS history, an investor can see the objective dynamics of capitalization. For Processa Pharmaceuticals (PCSA), this trend reflects the development cost of the CAP7 platform. Growth in this metric would confirm the successful scaling of the oncology pipeline.

Competing companies

Olema Pharmaceuticals - Net earnings per share (EPS TTM)|PBYI - Net earnings per share (EPS TTM)|Greenwich LifeSciences, Inc. (GLSI) - Earnings per share for the last twelve months|Earnings per share for the last 12 months ZNTL|MGNX (MacroGenics Corp) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Cytori Therapeutics (PSTV)|Net earnings per share (EPS TTM) EGRX